Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
复制标题
DOI：
10.1007/s12094-012-0779-1
复制
发表时间：
2012-03-01
影响因子：
3.4
通讯作者：
Martin, Miguel
中科院分区：
文献类型：
--
作者：
Romero, Atocha;Caldes, Trinidad;Martin, Miguel
由于人们认为以蒽环类药物为基础的化疗有益于乳腺癌患者，因此经常在乳腺癌的辅助治疗中使用蒽环类药物。尽管如此，这些药物都有严重的副作用，临床实践中有必要使用预测因素，如对蒽环类药物的敏感性。拓扑异构酶2α(TOP2A)被认为是这些药物的分子靶点。在接受蒽环类药物治疗的乳腺癌患者中，TOP2A扩增和过度表达的潜在预测价值已被广泛研究。然而，结果并不是决定性的。在这篇文章中，我们回顾了一些已发表的研究，涉及TOP2A的预测价值，以及该酶的细胞功能和在乳腺癌组织中的地位。
Anthracyclines are frequently used in the adjuvant setting for breast cancer treatment since it is considered that anthracycline-based chemotherapy treatment benefi ts breast cancer patients. Nonetheless, these drugs are associated with severe side effects and predictive factors, for sensitivity to anthracyclines, are warranted in clinical practice. Topoisomerase 2 alpha (TOP2A) is considered to be the molecular target of these drugs. The potential predictive value of TOP2A amplifi cation and overexpression has been extensively studied in breast cancer patients treated with anthracyclines. However, results are not conclusive. In this paper, we review some of the published studies addressing the predictive value of TOP2A as well as the cellular functions of this enzyme and its status in breast cancer tissue.